Zydus receives final Approval from the USFDA for Doxepin Hydrochloride Capsules USP, 150 mg

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereinafter referred to as "Zydus") has received final approval for Doxepin Hydrochloride Capsules USP, 150 mg (USRLD: Sinequan® Capsules) from the United States Food and Drug Administration (USFDA).

Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety. It helps improve moods and feelings of well-being, relieves anxiety and tension, helps sleep better and increases the energy level. The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

Doxepin Hydrochloride Capsules USP, 150 mg had annual sales of USD 2.11 mn in the United States (IQVIA MAT Jan. 2023).

The group now has 353 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 482.35 as compared to the previous close of Rs. 478.55. The total number of shares traded during the day was 36697 in over 1419 trades.

The stock hit an intraday high of Rs. 484.50 and intraday low of 478.20. The net turnover during the day was Rs. 17640470.00.

(*as of 31st December 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals FinalApproval DoxepinHydrochlorideCapsules USFDA